Found: 5
Select item for more details and to access through your institution.
ORY-2001: AN EPIGENETIC DRUG FOR THE TREATMENT OF COGNITION DEFECTS IN ALZHEIMER’S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1192, doi. 10.1016/j.jalz.2016.07.149
- By:
- Publication type:
- Article
The dual lsd1/maob inhibitor ory2001 prevents the development of the memory deficit in samp8 mice through induction of neuronal plasticity and reduction of neuroinflammation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P905, doi. 10.1016/j.jalz.2015.08.146
- By:
- Publication type:
- Article
Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations.
- Published in:
- PLoS ONE, 2020, v. 15, n. 5, p. 1, doi. 10.1371/journal.pone.0233468
- By:
- Publication type:
- Article
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
- Published in:
- CNS Drugs, 2021, v. 35, n. 3, p. 331, doi. 10.1007/s40263-021-00797-x
- By:
- Publication type:
- Article
Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 7, p. N.PAG, doi. 10.3390/pharmaceutics14071420
- By:
- Publication type:
- Article